Home Journals Articles Updates About
CN
image
收藏切换
Efficacy and safety analysis of sugemalimab as first-line treatment for non-small cell lung cancer
收藏切换
Fen LIU1, Gui-sen YIN2, Yong PAN1, Xia YUAN3, Jin-lan LI1, *
Chinese Journal of New Drugs | 2026, 35(14) : 1553 - 1558
Less
收藏切换
Chinese Journal of New Drugs | 2026, 35(14): 1553-1558
Efficacy and safety analysis of sugemalimab as first-line treatment for non-small cell lung cancer
Full
Fen LIU1, Gui-sen YIN2, Yong PAN1, Xia YUAN3, Jin-lan LI1, *
Affiliations
  • 1Department of Pharmacy, Affiliated Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China
  • 2Department of Clinical Pharmacy, Yantai Traditional Chinese Medicine Hospital, Yantai 264000, China
  • 3Department of Gastroenterology and Urology, Affiliated Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China
Published: 2026-07-30 doi: 10.20251/j.cnki.1003-3734.2026.14.014
Outline
收藏切换
Objective:

To analyze the efficacy and safety of sugemalimab as first-line treatment for non-small cell lung cancer (NSCLC) based on real-world data and provide guidance for its rational clinical application.

Methods:

The clinical data of NSCLC patients hospitalized at a specialized cancer hospital from June 2022 to December 2024 and receiving first-line sugemalimab treatment were retrospectively collected. Statistical analyses were performed on efficacy, safety profiles, and influencing factors.

Results:

Among 81 NSCLC patients treated with sugemalimab, the median progression-free survival (PFS) was 13.6 months (10.6-NA, 95%CI), with an objective response rate (ORR) of 58.0% and a disease control rate (DCR) of 95.0%. Patients with lung adenocarcinoma exhibited longer PFS compared to those with squamous cell carcinoma (17.2 vs 11.3 months, P=0.036). The incidence of all-grade adverse drug reactions (ADRs) was 33.3%, with grade 3~4 ADRs occurring in 7.6% of patients. No grade 5 ADRs were observed. Myelosuppression was the most common ADR across all grades and severe cases. COX regression analysis identified pathological type, metastatic sites, and pre-treatment albumin levels as potential prognostic factors.

Conclusion:

Sugemalimab demonstrates favorable efficacy and safety as a first-line treatment for NSCLC in real-world clinical practice.

real-world study  /  sugemalimab  /  non-small cell lung cancer
刘芬, 尹桂森, 潘勇, 袁霞, 李金兰. 舒格利单抗一线治疗非小细胞肺癌的疗效和安全性分析. 中国新药杂志, 2026 , 35 (14) : 1553 -1558 . DOI: 10.20251/j.cnki.1003-3734.2026.14.014
Fen LIU, Gui-sen YIN, Yong PAN, Xia YUAN, Jin-lan LI. Efficacy and safety analysis of sugemalimab as first-line treatment for non-small cell lung cancer[J]. Chinese Journal of New Drugs, 2026 , 35 (14) : 1553 -1558 . DOI: 10.20251/j.cnki.1003-3734.2026.14.014
Appendix
Less
Year 2026 volume 35 Issue 14
57
11
Cite this Article
BibTeX
Article Info
doi: 10.20251/j.cnki.1003-3734.2026.14.014
  • Online Date：2026-10-26
  • Published：2026-07-30
Article Data
Affiliations
History
  • Accepted：2025-07-02
Funding
Affiliations
    1Department of Pharmacy, Affiliated Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China
    2Department of Clinical Pharmacy, Yantai Traditional Chinese Medicine Hospital, Yantai 264000, China
    3Department of Gastroenterology and Urology, Affiliated Tumor Hospital of Xiangya School of Medicine, Central South University, Changsha 410011, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/10.20251/j.cnki.1003-3734.2026.14.014
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62662699(Operation and Technical Support)
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House